ILMOFOSINE

Suppliers

Names

[ CAS No. ]:
83519-04-4

[ Name ]:
ILMOFOSINE

Chemical & Physical Properties

[ Molecular Formula ]:
C26H56NO5PS

[ Molecular Weight ]:
525.76500

[ Exact Mass ]:
525.36200

[ PSA ]:
102.93000

[ LogP ]:
7.74150

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
JH4758000
CHEMICAL NAME :
3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
CAS REGISTRY NUMBER :
83519-04-4
LAST UPDATED :
199612
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C26-H56-N-O5-P-S
MOLECULAR WEIGHT :
525.86

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
253 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
74 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
615 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
113 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Human Cells - not otherwise specified
DOSE/DURATION :
1 mg/L
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 43,5538,1983

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301

[ Precautionary Statements ]:
P301 + P310

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ Hazard Codes ]:
Xn: Harmful;

[ Risk Phrases ]:
22

[ RIDADR ]:
UN 2811 6.1/PG 3

[ RTECS ]:
JH4758000

Synthetic Route

Click to get detail synthetic route

Articles

Phase I trial of ilmofosine as a 24 hour infusion weekly.

Invest. New Drugs 13(3) , 205-10, (1995)

Ilmofosine, an ether lipid derivative of lysophosphatidylcholine has antineoplastic activity in vitro and in vivo. Maximum efficacy in preclinical models is associated with prolonged exposure to the d...

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.

Invest. New Drugs 14(2) , 219-22, (1996)

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and ...

Structure-function relationships of alkyl-lysophospholipid analogs in selective antitumor activity.

Lipids 28(6) , 511-6, (1993)

This investigation was initiated in order to delineate the structure-function relationship of the anticancer alkyl-lysophospholipids and assess their degree of selective cytotoxicity toward neoplastic...


More Articles

Related Compounds

  • Ilmofosine
  • I(2)-D-Galactopyranoside, (2I+/-,3I(2),5I+/-,6I(2),22I+/-,25R)-26-(I(2)-D-glucopyranosyloxy)-2,6-dihydroxy-22-methoxyfurostan-3-yl O-I(2)-D-glucopyranosyl-(1a2)-O-[I(2)-D-xylopyranosyl-(1a3)]-O-I(2)-D-glucopyranosyl-(1a4)-
  • 1-Chloro-4-methyl-2-(2-nitroethenyl)benzene
  • 4-(1H-imidazol-1-yl)-2-methylbenzoicacidhydrochloride
  • 2-{5H,6H-imidazo[2,1-b][1,3]thiazol-2-yl}aceticacidhydrobromide
  • 4-methyl-5-(2-methyloxiran-2-yl)-1H-imidazole
  • Pyridinium, 1-[4-[[3-[(aminocarbonyl)amino]-4-[2-(3,6,8-trisulfo-2-naphthalenyl)diazenyl]phenyl]amino]-6-[[4-[2-(4-sulfophenyl)diazenyl]phenyl]amino]-1,3,5-triazin-2-yl]-3-carboxy-, inner salt
  • Begoniifolide D
  • 3-[(1R,2R,4Z,6R)-4-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methyl-6-triethylsilyloxyheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2,6-bis[[tert-butyl(diphenyl)silyl]oxy]-3-methylidenecyclohexyl]oxypropoxy-tert-butyl-diphenylsilane
  • L-Mannopyranose, O-I(2)-D-glucopyranuronosyl-(1a3)-O-[O-I(2)-D-glucopyranuronosyl-(1a3)-O-I+/--D-galactopyranuronosyl-(1a2)-6-deoxy-I+/--L-mannopyranosyl-(1a4)]-O-I+/--D-galactopyranuronosyl-(1a2)-6-deoxy-
  • 2H-Naphtho[1,2-d]triazole-5-sulfonic acid, 2-[4-[2-[4-[[3-ethoxy-4-[[1-hydroxy-6-(phenylamino)-3-sulfo-2-naphthalenyl]azo]-7-sulfo-1-naphthalenyl]azo]-2-sulfophenyl]ethenyl]-3-sulfophenyl]-
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.